Aehr Test Systems filings document material events, operating results, capital actions and governance matters for a semiconductor test and burn-in equipment company. Recent Form 8-K disclosures include quarterly financial-result releases covering revenue, bookings, backlog, cash position and GAAP and non-GAAP earnings measures.
The filing record also includes capital-structure disclosures tied to an at-the-market common stock offering under a Form S-3 registration statement, along with proxy and annual meeting materials. Those governance filings address director elections, shareholder voting results, amendments to the company’s equity incentive and employee stock purchase plans, auditor ratification and executive-compensation matters.
Aehr Test Systems reported proposed resale transactions on Form 144 by Geoffrey Scott. The filing lists a sale of 40,000 shares dated 04/09/2026 for $2,718,978.35 and a sale of 10,000 shares dated 04/21/2026 for $910,000. The transactions are identified as common stock sales for cash.
Alberto Salamone submitted a Form 144 notice for the proposed sale of 15,000 shares of Common Stock. The filing shows a trade date 04/20/2026 and a reported value of $1,343,589.55. The securities were issued as restricted stock vesting on 08/01/2024, tied to compensation.
AEHR Test Systems filing on Form 144 reports an insider disposition of 40,000 shares of Common Stock on 04/09/2026, with proceeds listed as $2,718,978.35. The filing references a prior private placement of 100,000 shares dated 11/24/2014 and shows 31,453,254 shares on record with a date of 04/21/2026.
AEHR TEST SYSTEMS executive Alistair N. Sporck reported updated holdings of company stock. A Form 4 entry shows 341 shares of Common Stock were withheld at $83.86 per share to satisfy tax obligations upon the vesting of restricted stock units, which the footnote clarifies is not an open-market sale.
After this tax-withholding transaction, Sporck directly holds 20,294 shares of Common Stock, and an additional 7,177 shares are held indirectly through a trust. The disclosed direct holdings figure also includes shares underlying unvested restricted stock units.
Aehr Test Systems completed sales under its at-the-market equity offering program, generating aggregate gross proceeds of approximately $60.0 million from common stock issuances. The shares were sold under an effective Form S-3 shelf registration that registered up to $100.0 million of securities, using a prospectus supplement dated April 8, 2026.
Aehr Test Systems executive Vernon Rogers sold 2,431 shares of Common Stock in an open-market transaction at $90.00 per share. After this sale, he directly holds 159,202 shares. A footnote explains that this remaining amount includes shares underlying unvested restricted stock units.
AEHR TEST SYSTEMS director Rhea J. Posedel reported an open-market sale of 7,500 shares of Common Stock at $88.09 per share through a trust. After this indirect transaction, the trust holds 396,979 shares. A separate entry shows 71,163 shares held directly, which includes shares subject to unvested restricted stock units.
AEHR Corporation affiliate reported multiple common‑stock dispositions. Rhea J. Posedel reported proposed and completed sales of Common shares under Form 144. The excerpt lists sales on 04/17/2026 (7,500 shares for $615,000), 04/16/2026 (15,000 shares for $1,210,800), 04/09/2026 (30,000 shares for $2,100,000) and 02/13/2026 (13,998 shares for $420,151.36). The filing also shows 7,500 shares listed as securities to be sold from a compensation grant dated 10/20/2020.
AEHR reported proposed and recent open-market sales of common stock on a Form 144 notice. The filing lists a proposed transfer tied to compensation dated 04/03/2026 and three completed sales by Vernon Rogers: 10,888 shares on 04/10/2026 for $762,160, 5,000 shares on 04/16/2026 for $434,400, and 5,000 shares on 04/20/2026 for $450,000.